ASX/Media Release 27 July 2018 Botanix expands clinical...

ASX/Media Release
27 July 2018
Botanix expands clinical capabilities
Key highlights
• Botanix has expanded its clinical capabilities with the appointment of a Chief Medical Officer and Senior Director of Clinical Operations
• Dr Stephane Levy and Ms Jillian Chapas-Reed join the Company to help accelerate the BTX 1503 acne and BTX 1204 atopic dermatitis Phase 2 clinical trials
• Appointments bring significant clinical expertise in acne, dermatitis and psoriasis and extensive late stage clinical development experience to Botanix
• Botanix is fully funded to complete two Phase 2 clinical trials in multi-billion dollar markets and is progressing other exciting dermatology pipeline products
Philadelphia PA and Sydney Australia, 27 July 2018: Medical dermatology company Botanix Pharmaceuticals (“Botanix” or “the Company”) today announced the appointment of two highly qualified global pharmaceutical industry executives to expand the Company’s clinical development capabilities. The Company appointed Dr Stephane Levy as Chief Medical Officer and Ms Jillian Chapas-Reed as Senior Director of Clinical Operations.
Matt Callahan, Founder and Executive Director of Botanix said: “We are very pleased to welcome both Stephane and Jillian to the team. Both of them bring highly relevant experience and technical knowledge to Botanix, which will help accelerate development of our lead Phase 2 clinical programs in acne and atopic dermatitis, as well as our growing pipeline of dermatology products.”